Exploring the nature of atheroma and cardiovascular inflammation in vivo using positron emission tomography (PET)

British Journal of Radiology

Volumn 88, Issue 1053, 2015, Pages

  Buscombe, J R ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; SODIUM FLUORIDE; GALLIUM; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; AORTA ANEURYSM; ATHEROMA; ATHEROSCLEROSIS; CARDIAC GATED IMAGING; CARDIOVASCULAR INFLAMMATION; CORONARY ARTERY CALCIFICATION; FATTY ACID METABOLISM; GIANT CELL ARTERITIS; HUMAN; IN VIVO STUDY; POSITRON EMISSION TOMOGRAPHY; REVIEW; VASCULITIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; CORONARY BLOOD VESSEL; DIAGNOSTIC USE; PROCEDURES; SCINTISCANNING;

AORTIC ANEURYSM; ATHEROSCLEROSIS; CORONARY VESSELS; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HUMANS; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SODIUM FLUORIDE; VASCULAR CALCIFICATION; VASCULITIS;

EID: 84941712162     PISSN: 00071285     EISSN: 1748880X     Source Type: Journal    
DOI: 10.1259/bjr.20140648     Document Type: Review

References (34)

1. Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ, et al. EANM/ SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med 2013; 54: 647-58. doi: 10.2967/ jnumed.112.112524
2. Ogawa T, Hatazawa J, Inugami A, Murakami M, Fujita H, Shimosegawa E, et al. Carbon- 11-methionine PET evaluation of intracerebral hematoma: Distinguishing neoplastic from non-neoplastic hematoma. J Nucl Med 1995; 36: 2175-9.
3. Deng SM, Zhang B, Wu YW, Zhang W, Chen YY. Detection of glioma recurrence by 11Cmethionine positron emission tomography and dynamic susceptibility contrastenhanced magnetic resonance imaging: A meta-analysis. Nucl Med Commun 2013; 34: 758-66. doi: 10.1097/ MNM.0b013e328361f598
4. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006; 8: 36-42. doi: 10.1007/ s11307-005-0029-9
5. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011; 101: 369-75. doi: 10.1016/j. radonc.2011.07.029
6. Barrington S, Scarsbrook A. Evidence based indications for the use of PET-CT in the United Kingdom, London, UK: Royal College of Physicians; 2012.
7. Walter MA, Melzer RA, Schindler C, Müller- Brand J, Tyndall A, Nitzsche EU. The value of [18F]FDG-PET in the diagnosis of largevessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005; 32: 674-81. doi: 10.1007/ s00259-004-1757-9
8. Papathanasiou ND, Du Y, Menezes LJ, Almuhaideb A, Shastry M, Beynon H, et al. 18F-Fludeoxyglucose PET/CT in the evaluation of large-vessel vasculitis: Diagnostic performance and correlation with clinical and laboratory parameters. Br J Radiol 2012; 85: E188-94. doi: 10.1259/bjr/16422950
9. Besson FL, Parienti JJ, Bienvenu B, Prior JO, Costo S, Bouvard G, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2011; 38: 1764-72. doi: 10.1007/s00259-011-1830-0
10. Moustafa RR, Izquierdo-Garcia D, Fryer TD, Graves MJ, Rudd JH, Gillard JH, et al. Carotid plaque inflammation is associated with cerebral microembolism in patients with recent transient ischemic attack or stroke: A pilot study. Circ Cardiovasc Imaging 2010; 3: 536-41. doi: 10.1161/ CIRCIMAGING.110.938225
11. Rudd JH, Myers KS, Bansilal S, Machac J, Woodward M, Fuster V, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: A prospective fluorodeoxyglucose positronemission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2009; 2: 107-15. doi: 10.1161/ CIRCIMAGING.108.811752
12. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al Atherosclerosis inflammation imaging with 18F-FDG PET: Carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008; 49: 871-8. doi: 10.2967/jnumed.107.050294
13. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: Implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007; 50: 892-6. doi: 10.1016/j. jacc.2007.05.024
14. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006; 48: 1825-31. doi: 10.1016/j.jacc.2006.03.069
15. van Wijk DF, Sjouke B, Figueroa A, Emami H, van der Valk FM, MacNabb MH, et al. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. J Am Coll Cardiol 2014; 64: 1418-26. doi: 10.1016/j. jacc.2014.01.088
16. Naci H, Brugts JJ, Fleurence R, Ades AE. Comparative effects of statins on major cerebrovascular events: A multiple-treatments meta-analysis of placebo-controlled and active-comparator trials. QJM 2013; 106: 299-306. doi: 10.1093/qjmed/hct041
17. Kumar V, Boddeti DK. (68)Garadiopharmaceuticals for PET imaging of infection and inflammation. Recent Results Cancer Res 2013; 194: 189-219. doi: 10.1007/ 978-3-642-27994-2-11
18. Li X, Bauer W, Israel I, Kreissl MC, Weirather J, Richter D, et al. Targeting P-selectin by gallium-68-labeled fucoidan positron emission tomography for noninvasive characterization of vulnerable plaques: Correlation with in vivo 17.6T MRI. Arterioscler Thromb Vasc Biol 2014; 34: 1661-7. doi: 10.1161/ ATVBAHA.114.303485
19. Silvola J, Autio A, Luoto P, Jalkanen S, Roivainen A. Preliminary evaluation of novel 68Ga-DOTAVAP-PEG-P2 peptide targeting vascular adhesion protein-1. Clin Physiol Funct Imaging 2010; 30: 75-8. doi: 10.1111/ j.1475-097X.2009.00907.x
20. Rominger A, Saam T, Vogl E, Ubleis C, la Fougère C, Förster S, et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: Correlation with coronary calcium burden and risk factors. J Nucl Med 2010; 51: 193-7. doi: 10.2967/jnumed.109.070672
21. Reeps C, Essler M, Pelisek J, Seidl S, Eckstein HH, Krause BJ. Increased 18Ffluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/ computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. J Vasc Surg 2008; 48: 417-23. doi: 10.1016/j.jvs.2008.03.059
22. Courtois A, Nusgens BV, Hustinx R, Namur G, Gomez P, Somja J, et al. 18F-FDG uptake assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture. J Nucl Med 2013; 54: 1740-7. doi: 10.2967/ jnumed.112.115873
23. Palombo D, Morbelli S, Spinella G, Pane B, Marini C, Rousas N, et al. A positron emission tomography/computed tomography (PET/CT) evaluation of asymptomatic abdominal aortic aneurysms: Another point of view. Ann Vasc Surg 2012; 26: 491-9. doi: 10.1016/j.avsg.2011.05.038
24. Barwick TD, Lyons OT, Mikhaeel NG, Waltham M, O'Doherty MJ. 18F-FDG PETCT uptake is a feature of both normal diameter and aneurysmal aortic wall and is not related to aneurysm size. Eur J Nucl Med Mol Imaging 2014; 41: 2310-18. doi: 10.1007/ s00259-014-2865-9
25. Tochon-Danguy HJ, Sachinidis JI, Chan F, Chan JG, Hall C, Cher L, et al. Imaging and quantitation of the hypoxic cell fraction of viable tumor in an animal model of intracerebral high grade glioma using [18F] fluoromisonidazole (FMISO). Nucl Med Biol 2002; 29: 191-7. doi: 10.1016/S0969-8051 (01)00298-0
26. Joshi FR, Manavaki R, Fryer TD, Buscombe JR, Smith R, Figg N. Imaging of hypoxia and inflammation in carotid atherosclerosis with 18F-fluoromisonidazole and 18Ffluorodeoxyglucose positron emission tomography. Circulation 2013; 128: A14673.
27. Beer AJ, Pelisek J, Heider P, Saraste A, Reeps C, Metz S, et al. PET/CT imaging of integrin avb3 expression in human carotid atherosclerosis. JACC Cardiovasc Imaging 2014; 7: 178-87. doi: 10.1016/j.jcmg.2013.12.003
28. Derlin T, Habermann CR, Lengyel Z, Busch JD, Wisotzki C, Mester J, et al. Feasibility of 11C-acetate PET/CT for imaging of fatty acid synthesis in the atherosclerotic vessel wall. J Nucl Med 2011; 52: 1848-54. doi: 10.2967/ jnumed.111.095869
29. Kato K, Schober O, Ikeda M, Schäfers M, Ishigaki T, Kies P, et al. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging 2009; 36: 1622-8. doi: 10.1007/s00259-009-1152-7
30. Arad Y, Spadaro LA, Goodman K, Newstein D, Guerci AD. Prediction of coronary events with electron beam computed tomography. J Am Coll Cardiol 2000; 36: 1253-60. doi: 10.1016/S0735-1097(00)00872-X
31. Shah S, Bellam N, Leipsic J, Berman DS, Quyyumi A, Hausleiter J, et al. Prognostic significance of calcified plaque among symptomatic patients with nonobstructive coronary artery disease. J Nucl Cardiol 2014; 21: 453-66. doi: 10.1007/s12350-014-9865-9
32. Quirce R, Banzo I, Martínez-Rodríguez I, Jiménez-Bonilla JF, Rebollo M, Rubio-Vassallo A, et al. New insight of molecular imaging into the atheroma biology: (18)Ffluoride PET/CT and 18F-FDG PET/CT of 3 carotid plaques in a symptomatic neurologic patient. Clin Nucl Med 2013; 38: 451-2. doi: 10.1097/RLU.0b013e3182816280
33. Armstrong IS, Tonge CM, Arumugam P. Impact of point spread function modeling and time-of-flight on myocardial blood flow and myocardial flow reserve measurements for rubidium-82 cardiac PET. J Nucl Cardiol 2014; 21: 467-74. doi: 10.1007/s12350-014- 9858-8
34. Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial. Lancet 2014; 383: 705-13. doi: 10.1016/ S0140-6736(13)61754-7